What is the treatment for atrial flutter?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment for Atrial Flutter

The most effective treatment for atrial flutter is catheter ablation of the cavotricuspid isthmus (CTI), which has success rates exceeding 90% and should be considered first-line therapy for patients with symptomatic atrial flutter or flutter refractory to pharmacological rate control. 1, 2

Initial Management Based on Hemodynamic Status

Hemodynamically Unstable Patients

  • Immediate synchronized cardioversion is recommended for patients with atrial flutter who are hemodynamically unstable 1, 3
  • Cardioversion for atrial flutter can be successful at lower energy levels than for atrial fibrillation 1, 2
  • Appropriate anticoagulation considerations should be addressed prior to cardioversion when possible 3, 4

Hemodynamically Stable Patients

  • Treatment strategy can focus on either rate control or rhythm control 1, 3
  • For rate control: intravenous or oral beta blockers, diltiazem, or verapamil are first-line agents 1, 5
  • For rhythm control: oral dofetilide or intravenous ibutilide for pharmacological cardioversion, or elective synchronized cardioversion 1, 2

Rate Control Strategy

  • Intravenous diltiazem is the preferred calcium channel blocker due to its safety and efficacy profile 1, 3
  • Esmolol is generally the preferred intravenous beta blocker for acute rate control because of its rapid onset 5
  • Target heart rate should be <100 beats per minute at rest 6
  • Important medication considerations:
    • Avoid diltiazem and verapamil in patients with advanced heart failure, heart block, or sinus node dysfunction without pacemaker therapy 5, 7
    • Avoid calcium channel blockers and beta blockers in patients with pre-excitation due to risk of accelerated ventricular rates 5, 7
    • For patients with systolic heart failure where beta blockers are contraindicated or ineffective, intravenous amiodarone can be useful 3, 5

Rhythm Control Strategy

Acute Conversion Options

  • Elective synchronized cardioversion is indicated in stable patients when pursuing rhythm control 1, 3
  • Pharmacological cardioversion options:
    • Oral dofetilide or intravenous ibutilide (effective in approximately 60% of cases) 1, 2
    • Flecainide and propafenone can be used in patients without structural heart disease 2, 8
  • Rapid atrial pacing is useful for acute conversion in patients with pacing wires already in place (e.g., permanent pacemaker, ICD, temporary wires after cardiac surgery) 1, 3

Long-Term Rhythm Control

  • Catheter ablation of the CTI is the most effective long-term rhythm control strategy 1, 2
  • For patients not suitable for ablation, antiarrhythmic drugs can be used:
    • Amiodarone, dofetilide, or sotalol can maintain sinus rhythm 5, 8
    • Flecainide or propafenone may be considered only in patients without structural heart disease 5, 9

Anticoagulation Considerations

  • Antithrombotic therapy in patients with atrial flutter should follow the same protocols as for atrial fibrillation 1, 3
  • Risk of stroke in atrial flutter is significant, with reported rates of 3% annually 3, 5
  • For cardioversion of atrial flutter lasting ≥48 hours or of unknown duration, anticoagulation is recommended for at least 3 weeks before and 4 weeks after cardioversion 2, 4
  • Warfarin therapy with a target INR of 2.0-3.0 is recommended for patients with risk factors for stroke 4, 10

Important Clinical Considerations and Pitfalls

  • Rate control can be more difficult to achieve in atrial flutter than in atrial fibrillation due to less concealed AV nodal conduction 1, 5
  • Atrial flutter and atrial fibrillation frequently coexist—22-50% of patients develop atrial fibrillation within 14-30 months after CTI ablation 1, 5
  • Risk factors for developing atrial fibrillation after atrial flutter ablation include prior atrial fibrillation, depressed left ventricular function, structural heart disease, and increased left atrial size 1, 5
  • Using verapamil or diltiazem in patients with pre-excitation can precipitate ventricular fibrillation 3, 7
  • Insufficient monitoring for QT prolongation when using ibutilide for pharmacological cardioversion can lead to torsades de pointes 3, 5

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Rhythm Control Strategies for Atrial Flutter

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Initial Treatment for Atrial Flutter

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Treatment Approach for Rate-Controlled Atrial Flutter

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Atrial Flutter.

Current treatment options in cardiovascular medicine, 2001

Research

Management of atrial flutter.

Cardiology in review, 2001

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.